10/17/2017 | BKCV | Moody’s could raise Impax
|
8/22/2017 | BKCVHY | S&P cuts Impax, facilities, notes
|
4/13/2017 | BKCV | Moody’s drops Impax
|
11/23/2016 | BKCVHY | S&P downgrades Impax
|
8/9/2016 | BKCVIG | S&P cuts Impax convertibles, rates loans BBB-
|
8/4/2016 | BKCV | Moody’s assigns Ba2 to Impax facility
|
8/3/2016 | BK | Impax adds $400 million term loan; doubles revolver to $200 million
|
6/22/2016 | BKCV | Moody’s: Impax unchanged following acquisition
|
6/21/2016 | BK | Impax plans $400 million in term debt for purchase of generic products
|
9/15/2015 | BKCV | Moody’s rates Impax revolver Ba1
|
9/15/2015 | BKCV | S&P rates Impax convertibles BB
|
8/5/2015 | BK | Impax Laboratories obtains $100 million revolver due 2020 via RBC
|
3/10/2015 | BK | Market Commentary: Blue Coat second-lien up on buyout news; Ineos, Headwaters, Surgical Care changes surface
|
12/17/2014 | BK | Market Commentary: Impax Laboratories, Dealer Tire, TASC, Caraustar Industries, Amneal, ATI Physical break
|
12/4/2014 | BK | Moody’s assigns B1 to Impax CFR, loans
|
12/2/2014 | BK | Market Commentary: Novolex, Sonneborn, Total Merchant changes emerge; primary sees more than 10 deals launch
|
12/2/2014 | BK | S&P rates Impax CCR BB, loans BBB-
|
12/2/2014 | BK | Impax Laboratories launches $435 million loan at Libor plus 450 bps
|
12/1/2014 | BK | Market Commentary: TierPoint breaks; Royalty Pharma guidance surfaces; primary calendar continues to build
|
12/1/2014 | BK | Impax Laboratories to launch $435 million term loan on Tuesday
|
10/10/2014 | BK | Impax Labs gets $460 million facility from Barclays for acquisition
|